Company profile
PALATIN TECHNOLOGIES INC
NASDAQ:PTNBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NEUTROSPEC | approved | $0.3MQ2 2026 | 0 | — |
| PL-3994 | phase2 | — | 1 | withdrawn |
| PL-8177 | phase2 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02333071 | phase3 | completed | 2014-12-01 | 2016-07-01 | Palatin Technologies, Inc | 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT02338960 | phase3 | completed | 2015-01-01 | 2016-08-01 | Palatin Technologies, Inc | 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT06565611 | phase2 | active_not_recruiting | 2024-08-05 | 2025-02-05 | Palatin Technologies, Inc | A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity |
| NCT05201170 | phase3 | completed | 2021-12-30 | 2023-09-01 | Palatin Technologies, Inc | A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye |
| NCT05709444 | phase2 | completed | 2022-12-26 | 2024-04-26 | Palatin Technologies, Inc | A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 103928 | 2004-07-02 | BLA | PALATIN TECHNOLOGIES, INC. | |||||
Loading… | ||||||||